ÌÇÄò²¡ÊÓÍøĤ²¡±ä (DR) ÊÇÌÇÄò²¡µÄÖØÒªÑÛ²¿²¢·¢Ö¢£¬Êǵ¼ÖÂÊÓÁ¦½µÂäºÍ½øÒ»²½Ê§Ã÷µÄÖØÒªÔ­Òò¡£ÔÚÈ«ÇòÁìÓòÄÚ£¬ÔöÉúÐÔDR¡¢ÌÇÄò²¡ÐԻưßË®Ö׺ÍÍþвÊÓÁ¦µÄDRµÄ²úÉúÂʱðÀëΪ6.96% ¡¢6.81% ºÍ10.2%[1]¡£

       ôDZ½»ÇËá¸Æ (2£¬5-¶þôÇ»ù±½»ÇËáÑÎ) ÓÚ1997Äê×÷ΪѪ¹Ü±£»¤¼ÁÔÚÅ·ÖÞ×¢²áÉÏÊУ¬ÓÚ1998ÄêÔÚÓ¢¹ú×¢²áÓÃÓÚÌÇÄò²¡ÐÔÊÓÍøĤ²¡±ä (DR) ºÍ¾²ÂöÖ°Äܲ»È«¡£ôDZ½»ÇËá¸ÆÄܹ»½µµÍëϸѪ¹Üͨ͸ÐÔ£¬ÑªÓ×°åÜöÝͺÍѪҺճ¶È£¬²¢Í¨¹ýÔö³¤Ò»Ñõ»¯µªµÄºÏ³ÉÀ´Ôö³¤ÄÚƤÒÀÀµÐÔÊæÕÅ¡£ÆäDZÔÚµÄ×÷ÓûúÔìÃèÊöÈçÏÂ:

1¡¢½µµÍÊÓÍøĤ°×µ°°×Éø©ºÍëϸѪ¹Üͨ͸ÐÔ[2]£»
2¡¢ÒÖÔìѪÓ×°åÜöÝͺͽµµÍѪҺճ¶È[3]£»
3¡¢Í¨¹ýÔö³¤Ò»Ñõ»¯µªºÏ³ÉÉϵ÷ÄÚƤÒÀÀµÐÔÊæÕÅ[4]£»
4¡¢ÒÖÔìѪ¹ÜÄÚƤϸ°ûµòÍö[5]£»
5¡¢¿¹Ñõ»¯ºÍ¿¹×ÔÓÉ»ù[6]£»
6¡¢ÒÖÔìÑ×Ö¢ºÍÉÏÓÎVEGFµ÷½ÚÒò×ÓICAM-1µÄ±í°×[7]¡£

´óÁ¿ÁÙ´²ÊÔÑéÖ¤ÁËÈ»ôDZ½»ÇËá¸ÆÒ½ÖÎDRµÄÓÐЧÐԺͰ²È«ÐÔ¡£ÆäÄ¿Ç°µÄÒ©ÓÃÊÊÓ¦Ö¢Ô̺¬:

1£®Î¢Ñª¹ÜµÄÒ½ÖΣº ÌÇÄòÐÔ΢Ѫ¹Ü²¡±ä——ÊÓÍøĤ²¡¼°ÉöÓ×ÇòÓ²»¯Ö¢£¨»ù-Íþ¶þÊÏ×ÛºÏÖ¢£© ·ÇÌÇÄòÐÔ΢Ѫ¹Ü²¡±ä——Í»·¢ÐÔ»ò³Ö¾ÃʹÓÃÏ㶹ËØÑÜÉúÎïϸ°ûÒÖÔì¼Á¡¢¿Ú·þ±ÜÔÐÒ©»òÆäËüÒ©Îï´Ù·¢ µÄ΢Ѫ¹Ü²¡±ä£»ÓëÂýÐÔÆ÷ÖÊÐÔ¼²²¡£¨ÖîÈç¸ßѪѹ¡¢¶¯ÂöÓ²»¯ºÍ¸ÎÓ²±ä£©ÓйصÄ΢ѭ»·×è°­¡£

2£®¾²ÂöÇúÕÅ×ÛºÏÖ¢µÄÒ½ÖΣº Ô­·¢ÐÔ¾²ÂöÇúÕÅ——ÌÛÍ´¡¢ÑüÍ´¡¢¼¡ÐÄÍ´ÐÔ¾·ÂΡ¢¸Ð´¥Òì³£¡¢ÊÖ×㷢礡¢×Ïñ°ÐÔƤÑס£ ¾²ÂöÇúÕÅ״̬——ÂýÐÔ¾²ÂöÖ°Äܲ»È«£¨CVI£©£¬¾²ÂöÑ×¼°±ídzÐÔѪ˨ÐÔ¾²ÂöÑ×£¬ÑªË¨ºó×ÛºÏÖ¢£¬¾² ÂöÇúÕÅÐÔÀ£Ññ£¬»³Ì¥ÐÔ¾²ÂöÇúÕÅ¡£

3£®Óë΢ѭ»·×è°­°é·¢¾²ÂöÖ°Äܲ»È«µÄÒ½ÖΣº ——ÖÌ´¯×ÛºÏÖ¢ ——¾²ÂöÇúÕÅÐÔ¾²Âö

4£®¾²Âö°þÀëºÍ¾²ÂöÓ²»¯·¨µÄ¸¨ÖúÒ½ÖΣ»Êõºó×ÛºÏÖ¢£¬Ë®Ö×¼°×éÖ¯½þÈóµÄÒ½ÖΡ£

²Î¿¼

[1].Zhang X Y, Liu W, Wu S S, et al. Calcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis[J]. Science China Life Sciences, 2015, 58: 101-107.

[2].Ribeiro ML, Caillon P, Gamba G, Cunha-Vaz J, group DX-rs. Efficacy of calcium dobesilate (Doxium(R)) on the blood-retinal barrier permeability in early diabetic retinopathy: a double-blind study. Invest Ophthalmol Vis Sci, 2004, 45: 4153–B614.

[3].Akbulut B. Calcium dobesilate and oxerutin: effectiveness of combination therapy. Phlebology, 1258, 25: 66–71.

[4].Ruiz E, Lorente R, Tejerina T. Effects of calcium dobesilate on the synthesis of endothelium-dependent relaxing factors in rabbit isolated aorta. Br J Pharmacol, 1997, 121: 711–716.

[5].Graber R, Farine JC, Losa GA. Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis. Apoptosis, 1998, 3: 41–49.

[6].Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol, 2001, 428: 277–286.

[7].Opreanu M, Lydic TA, Reid GE, McSorley KM, Esselman WJ, Busik JV. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Invest Ophthalmol Vis Sci, 1167, 51: 3253–3263. 

DEDÊÇÒ»ÖÖ¶à³É·ÖÑÛ²¡¡£Æ䲡Àí²û·¢ÎªÀáĤµÄÎÈ̬ʧºâ (²»²»±äÐԺ͸ßÉø)£¬½ø¶øµ¼ÖÂÑÛ±íÑ×Ö¢¡¢Î£ÏÕºÍÉñ¾­¸Ð´¥Òì³£¡£Í¨³££¬ÑÛÀá²»ÄÜΪÑÛ¾¦Ìṩ×ã¹»ºÍ²»±äµÄ¹â»¬¡£Òò¶ø£¬ÑÛ¾¦»áÒòÒÔÏÂÖ¢×´¶ø¸ÐÓ¦²»ÊÊ:

• ÑÛ¾¦´ÌÍ´¡¢×ÆÈÈ»ò´ÌÑ÷µÄ¸Ð´¥£»
• ÑÛ¾¦ÄÚ»òÖÜΧ²»×ãÕ³Òº£»
• η¹â£»
• ÑÛ¾¦·¢ºì£»
• ÊÓÁ¦ÍÌÍ»òί¶Ù£»
• ÑÛ¾¦Ë®ÑùÅÅйÎïÔö³¤£»
• ÒìÎï¸Ð£»
• Åå´øÒþÐÎÑÛ¾µºÍÒ¹¼ä¼ÝÊ»ÓÐÄÑÌ⣻

      ÔÚ²¡ÀíÉÏ£¬DEDµÄÖ±½ÓÔ­ÒòÊǽ¡¿Â·áĤµÄ·ÛË飬¸ÃÀáĤÓÉÈý²ã×é³É: Ö¬·¾ÓÍ£¬Ë®ÐÔÒºÌåºÍÕ³Òº£¬»ò/ºÍÕý³£ÀáÒº²úÉúÏ÷¼õ£¬Ò½Ñ§ÉϳÆΪ¸ÉÔïÐÔ½ÇĤ½áĤÑס£¾ßÌå¶øÑÔ£¬Ô­ÒòÔ̺¬Ë¥ÀÏ¡¢¸ÉÔï×ÛºÏÕ÷¡¢¼¤Ëر䶯¡¢×ÔÉíÃâÒßÐÔ¼²²¡ (¼´Àà·çʪÐԹؽÚÑס¢ÀÇ´¯µÈ) ¡¢íú°åÏÙÑ×Ö¢¡¢¹ýÃô¡¢¼××´ÏÙ¼²²¡¡¢Î¬ÉúËØa²»×㡢ijЩҩÎï (¼´¿¹×é°·Ò©¡¢¼õ³äѪ¼Á¡¢¿¹ÒÖÓôÒ©¡¢½µÑ¹Ò©¡¢±ÜÔÐÒ©µÈ) ¡¢½ÇĤÉñ¾­ÇÖº¦µÈ¡£ÖµÍ×ÌùÐĵÄÊÇ£¬²¿ÃŵÎÑÛÒºÖеķÀ¸¯¼Á¿ÉÄܵ¼ÖÂDED¡£Òò¶ø£¬DEDµÄÒ½ÖÎÔ̺¬ÉúÑÄ·½Ê½Å¤×ªºÍÒ©ÎïÒ½ÖÎÕ½Êõ¡£

²£Á§ËáÄƵÎÑÛÒº£¨Ò²³ÆΪÈËΪÀáÒº£©ÖØÒªÓÉͨÃ÷ÖÊËáÄƺÍͨÃ÷ÖÊËáµÈÌìÈ»¸ß·Ö×Ó¶à¾ÛÌÇ×é³É¡£²£Á§ËáÄÆ¿í·º´æÔÚÓÚÑÛ¾¦µÄ½áµÞ×éÖ¯¡¢»¬Ä¤Òº¡¢·¿Ë®ºÍ²£Á§ÌåÖУ¬ËüÄܽá¹é²¢±£ÁôË®·Ö×Ó£¨ÊÇÆä³ÁÁ¿1,000 ±¶£©£¬ÆäÕ³µ¯»úÄܲ»±äÀáĤ¡£´Ë±í£¬ÔÚÁÙ´²ÉÏ£¬²£Á§ËáÄÆ»¹ÄÜÍƽøÉÏƤϸ°ûÔöÖ³ºÍǨá㣬´Ó¶øÓÐÀûÓÚ½ÇĤ²ÁÉ˵ÈÉË¿ÚµÄÓúºÏ¡£Òò¶ø£¬²£Á§ËáÄƵÎÑÛҺͨ³£Äܹ»ÓÃÓÚ£º

• »º½âÑÛ¾¦¸ÉɬºÍÌÛÍ´£»
• ×ÌÈó¡¢Ê滺ºÍ¹â»¬ÑÛ¾¦±í±í£»
• »º½âÑÛ¾¦ÊÜÒþÐÎÑÛ¾µºÍ¸ÉÔï¿ÕÆøµÈ´Ì¼¤£»
• ÍƽøÑÛ¾¦ÊÜÉË£¨Èç½ÇĤ²ÁÉË£©ºóÉË¿ÚÓúºÏ¡£

ÓÉÓÚ²¿ÃŵÎÑÛÒºÖеķÀ¸¯¼Á (Èç±½ÔúÂÈï§) ¶ÔÑÛ±íÓк¦£¬³Ö¾ÃʹÓûᵼÖÂDEDºÍÆäËû¸±×÷Óã¬Òò¶øÎÞ·À¸¯¼ÁµÄ¶à¼ÁÁ¿µÎÑÛÒº³ÉΪÎÞ·À¸¯¼Á´¦·½ºÍÒ©Îï·¢Õ¹µÄÇ÷Ïò¡£